Bluebird Bio Works to Resolve Financial Reporting Delays
Express News | Bluebird bio Announces Receipt of Expected Notices From Nasdaq
Bluebird Bio Announces Receipt of Expected Notices From Nasdaq
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)
What 4 Analyst Ratings Have To Say About Bluebird Bio
Bluebird Bio Shares Are Trading Lower After JP Morgan Downgraded the Stock From Overweight to Neutral and Multiple Firms Lowered Their Respective Price Targets on the Stock.
RBC Capital Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $4
Bluebird Bio Price Target Maintained With a $4.00/Share by RBC Capital
Bluebird Bio Is Maintained at Overweight by Barclays
BofA Securities Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $3
A Quick Look at Today's Ratings for Bluebird Bio(BLUE.US), With a Forecast Between $3 to $4
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Express News | Bluebird bio Inc : BofA Global Research Cuts Price Objective to $3 From $4
Bluebird Bio Analyst Ratings
Analysts Conflicted on These Healthcare Names: Verrica Pharmaceuticals (VRCA), Celcuity (CELC) and Bluebird Bio (BLUE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and Irhythm Technologies (IRTC)
Maintaining Buy Rating on Bluebird Bio Amidst Conservative Revenue Projections for Lyfgenia
Bluebird Bio (BLUE) Receives a Buy From Barclays
Express News | Bluebird bio Inc : Baird Cuts Target Price to $6 From $7
No Data